Paradigm Biopharmaceuticals Ltd
ASX:PAR

Watchlist Manager
Paradigm Biopharmaceuticals Ltd Logo
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Watchlist
Price: 0.325 AUD 20.37% Market Closed
Market Cap: 113.9m AUD
Have any thoughts about
Paradigm Biopharmaceuticals Ltd?
Write Note

Intrinsic Value

PAR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one PAR stock under the Base Case scenario is 0.396 AUD. Compared to the current market price of 0.325 AUD, Paradigm Biopharmaceuticals Ltd is Undervalued by 18%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PAR Intrinsic Value
0.396 AUD
Undervaluation 18%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Paradigm Biopharmaceuticals Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PAR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PAR?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Paradigm Biopharmaceuticals Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Paradigm Biopharmaceuticals Ltd

Provide an overview of the primary business activities
of Paradigm Biopharmaceuticals Ltd.

What unique competitive advantages
does Paradigm Biopharmaceuticals Ltd hold over its rivals?

What risks and challenges
does Paradigm Biopharmaceuticals Ltd face in the near future?

Has there been any significant insider trading activity
in Paradigm Biopharmaceuticals Ltd recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Paradigm Biopharmaceuticals Ltd.

Provide P/S
for Paradigm Biopharmaceuticals Ltd.

Provide P/E
for Paradigm Biopharmaceuticals Ltd.

Provide P/OCF
for Paradigm Biopharmaceuticals Ltd.

Provide P/FCFE
for Paradigm Biopharmaceuticals Ltd.

Provide P/B
for Paradigm Biopharmaceuticals Ltd.

Provide EV/S
for Paradigm Biopharmaceuticals Ltd.

Provide EV/GP
for Paradigm Biopharmaceuticals Ltd.

Provide EV/EBITDA
for Paradigm Biopharmaceuticals Ltd.

Provide EV/EBIT
for Paradigm Biopharmaceuticals Ltd.

Provide EV/OCF
for Paradigm Biopharmaceuticals Ltd.

Provide EV/FCFF
for Paradigm Biopharmaceuticals Ltd.

Provide EV/IC
for Paradigm Biopharmaceuticals Ltd.

Show me price targets
for Paradigm Biopharmaceuticals Ltd made by professional analysts.

What are the Revenue projections
for Paradigm Biopharmaceuticals Ltd?

How accurate were the past Revenue estimates
for Paradigm Biopharmaceuticals Ltd?

What are the Net Income projections
for Paradigm Biopharmaceuticals Ltd?

How accurate were the past Net Income estimates
for Paradigm Biopharmaceuticals Ltd?

What are the EPS projections
for Paradigm Biopharmaceuticals Ltd?

How accurate were the past EPS estimates
for Paradigm Biopharmaceuticals Ltd?

What are the EBIT projections
for Paradigm Biopharmaceuticals Ltd?

How accurate were the past EBIT estimates
for Paradigm Biopharmaceuticals Ltd?

Compare the revenue forecasts
for Paradigm Biopharmaceuticals Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Paradigm Biopharmaceuticals Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Paradigm Biopharmaceuticals Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Paradigm Biopharmaceuticals Ltd compared to its peers.

Compare the P/E ratios
of Paradigm Biopharmaceuticals Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Paradigm Biopharmaceuticals Ltd with its peers.

Analyze the financial leverage
of Paradigm Biopharmaceuticals Ltd compared to its main competitors.

Show all profitability ratios
for Paradigm Biopharmaceuticals Ltd.

Provide ROE
for Paradigm Biopharmaceuticals Ltd.

Provide ROA
for Paradigm Biopharmaceuticals Ltd.

Provide ROIC
for Paradigm Biopharmaceuticals Ltd.

Provide ROCE
for Paradigm Biopharmaceuticals Ltd.

Provide Gross Margin
for Paradigm Biopharmaceuticals Ltd.

Provide Operating Margin
for Paradigm Biopharmaceuticals Ltd.

Provide Net Margin
for Paradigm Biopharmaceuticals Ltd.

Provide FCF Margin
for Paradigm Biopharmaceuticals Ltd.

Show all solvency ratios
for Paradigm Biopharmaceuticals Ltd.

Provide D/E Ratio
for Paradigm Biopharmaceuticals Ltd.

Provide D/A Ratio
for Paradigm Biopharmaceuticals Ltd.

Provide Interest Coverage Ratio
for Paradigm Biopharmaceuticals Ltd.

Provide Altman Z-Score Ratio
for Paradigm Biopharmaceuticals Ltd.

Provide Quick Ratio
for Paradigm Biopharmaceuticals Ltd.

Provide Current Ratio
for Paradigm Biopharmaceuticals Ltd.

Provide Cash Ratio
for Paradigm Biopharmaceuticals Ltd.

What is the historical Revenue growth
over the last 5 years for Paradigm Biopharmaceuticals Ltd?

What is the historical Net Income growth
over the last 5 years for Paradigm Biopharmaceuticals Ltd?

What is the current Free Cash Flow
of Paradigm Biopharmaceuticals Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Paradigm Biopharmaceuticals Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Paradigm Biopharmaceuticals Ltd

Current Assets 24.3m
Cash & Short-Term Investments 17.9m
Receivables 5.1m
Other Current Assets 1.3m
Non-Current Assets 3.1m
PP&E 189.7k
Intangibles 2.9m
Current Liabilities 3.4m
Accounts Payable 2.8m
Accrued Liabilities 416.8k
Other Current Liabilities 121.8k
Non-Current Liabilities 224.5k
Long-Term Debt 20.6k
Other Non-Current Liabilities 204k
Efficiency

Earnings Waterfall
Paradigm Biopharmaceuticals Ltd

Revenue
6.5m AUD
Cost of Revenue
-9k AUD
Gross Profit
6.5m AUD
Operating Expenses
-65.1m AUD
Operating Income
-58.6m AUD
Other Expenses
-60.9k AUD
Net Income
-58.7m AUD

Free Cash Flow Analysis
Paradigm Biopharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

PAR Profitability Score
Profitability Due Diligence

Paradigm Biopharmaceuticals Ltd's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Negative 3-Years Revenue Growth
Negative 1-Year Revenue Growth
Declining ROE
16/100
Profitability
Score

Paradigm Biopharmaceuticals Ltd's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

PAR Solvency Score
Solvency Due Diligence

Paradigm Biopharmaceuticals Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
79/100
Solvency
Score

Paradigm Biopharmaceuticals Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PAR Price Targets Summary
Paradigm Biopharmaceuticals Ltd

Wall Street analysts forecast PAR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PAR is 0.479 AUD with a low forecast of 0.475 AUD and a high forecast of 0.494 AUD.

Lowest
Price Target
0.475 AUD
46% Upside
Average
Price Target
0.479 AUD
48% Upside
Highest
Price Target
0.494 AUD
52% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PAR?

Click here to dive deeper.

Dividends

Paradigm Biopharmaceuticals Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for PAR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

PAR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Paradigm Biopharmaceuticals Ltd Logo
Paradigm Biopharmaceuticals Ltd

Country

Australia

Industry

Biotechnology

Market Cap

113.9m AUD

Dividend Yield

0%

Description

Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company, engages in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is developing and commercializing injectable Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), chronic heart failure (CHF) and alphaviral arthritis (Ross River Virus and Chikungunya). Its product candidate PPS is a non-opioid drug treatment for the chronic pain and joint stiffness of Osteoarthritis. Its product candidate PPS is providing treatment for Mucopolysaccharidosis, an inherited defect in the catabolism of sulfated components of connective tissue known as glycosaminoglycans (GAGs). Its product candidate PPS is used to treat Ross River virus and Chikungunya, an arthritogenic alphaviruses transmitted by mosquito bites.

Contact

VICTORIA
Melbourne
L 15 500 Collins Street
+61396295566.0
paradigmbiopharma.com

IPO

2015-08-19

Employees

-

Officers

Founder, MD & Executive Chairman
Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC
Chief Medical Officer and Executive Director
Dr. Donna L. Skerrett M.D., MS
Company Secretary & CFO
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A.
Chief Scientific Officer
Dr. Ravi Krishnan
Director of Investor Relations
Mr. Simon White
Global Head of Drug Safety & MPS
Dr. Michael Imperiale
Show More
Commercial Head
Ms. Beverley Huttmann
Global Head of Regulatory Affairs
Ms. Michelle Coffey
Global Clinical Head of OA
Dr. Mukesh Ahuja
Show Less

See Also

Discover More
What is the Intrinsic Value of one PAR stock?

The intrinsic value of one PAR stock under the Base Case scenario is 0.396 AUD.

Is PAR stock undervalued or overvalued?

Compared to the current market price of 0.325 AUD, Paradigm Biopharmaceuticals Ltd is Undervalued by 18%.

Back to Top